- Home
- SERA vs VRCA Comparison
SERA vs VRCA Comparison
Compare SERA & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SERA | VRCA |
|---|---|---|
| Founded | 2008 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.3M | 112.4M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SERA | VRCA |
|---|---|---|
| Price | $2.25 | $5.59 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 21.1K | ★ 125.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.66 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $77,000.00 | N/A |
| Revenue This Year | $25.84 | $372.93 |
| Revenue Next Year | $715.79 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.37 | $0.39 |
| 52 Week High | $4.35 | $9.82 |
Technical Indicators
Market Signals| Indicator | SERA | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 33.63 | 36.71 |
| Support Level | $2.26 | $5.29 |
| Resistance Level | $3.45 | $6.50 |
| Average True Range (ATR) | 0.20 | 0.50 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 22.00 | 13.05 |
Price Performance
Historical ComparisonAbout SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.